Disease progression and progression-free survival. (A) Disease progression or relapse after allo-SCT in patients with (n = 69; solid line) and without (n = 31; dashed line) GVHD (whatever its form or grade), (B) progression-free survival according to GVHD, and (C) progression-free survival according to ATG dose. Dashed line indicates high ATG dose; solid line, low ATG dose.